Valuation: Evofem Biosciences, Inc.

Market Cap 1L 1L 94.64T 85.61T 2L 1.05Cr 2L 11.44L 5L 56.63L 4L 4L 1.79Cr P/E 2024
-0.08x
P/E 2025 26.6x
Enterprise Value 5.45Cr 4.97Cr 4.6Cr 4.16Cr 7.8Cr 509.27Cr 8.17Cr 56Cr 22Cr 275.2Cr 20Cr 20Cr 871.74Cr EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+27.00%
1 week-85.40%
Current month-85.89%
1 month-86.56%
3 months-88.86%
6 months-86.12%
Current year-91.09%
1 week 1
Extreme 1
9.9
1 month 1
Extreme 1
10.5
Current year 1
Extreme 1
16.2
1 year 1
Extreme 1
20.4
3 years 1
Extreme 1
338.98
5 years 1
Extreme 1
15,18,560.18
10 years 1
Extreme 1
3,53,20,584.93
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+27.00%-85.40%-91.45%-98.79% 1L
-2.29%-5.34%+28.73%+128.34% 1,20400Cr
-2.04%-5.78%+31.91%+78.34% 64TCr
-0.86%-3.71%+21.74%+105.02% 50TCr
-0.14%-1.58%+27.74%+67.95% 38TCr
-3.61%-9.62%+39.73%+30.53% 33TCr
+0.52%-4.68%+27.25%+51.61% 28TCr
+1.07%-3.78%-1.44%+33.13% 27TCr
-1.14%-6.05%+28.16%+65.35% 24TCr
-1.45%-0.85%+30.03%+120.72% 21TCr
Average +2.70%-12.59%+14.24%+58.22% 41TCr
Weighted average by Cap. +0.08%-4.71%+27.08%+88.16%

Financials

2024 2025
Net sales 1.94Cr 1.76Cr 1.63Cr 1.48Cr 2.77Cr 180.84Cr 2.9Cr 20Cr 7.83Cr 98Cr 7.26Cr 7.11Cr 309.55Cr 2.02Cr 1.84Cr 1.7Cr 1.54Cr 2.89Cr 188.5Cr 3.02Cr 21Cr 8.16Cr 101.86Cr 7.57Cr 7.41Cr 322.66Cr
Net income -88.6L -80.72L -74.73L -67.59L -1.27Cr -83Cr -1.33Cr -9.03Cr -3.58Cr -45Cr -3.32Cr -3.25Cr -141.64Cr 4L 4L 3L 3L 6L 3.65Cr 6L 39.86L 15.81L 1.97Cr 14.67L 14.36L 6.25Cr
Net Debt 4.58Cr 4.18Cr 3.87Cr 3.5Cr 6.56Cr 428.12Cr 6.87Cr 47Cr 19Cr 231.34Cr 17Cr 17Cr 732.83Cr 5.44Cr 4.96Cr 4.59Cr 4.15Cr 7.79Cr 508.22Cr 8.15Cr 55Cr 22Cr 274.63Cr 20Cr 20Cr 869.94Cr
Projected Income Statement - Annual - Evofem Biosciences, Inc.
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
19/26/19 $1.270 +27.00% 553
18/26/18 $1.000 -84.50% 880
17/26/17 $6.450 -28.93% 1,796
16/26/16 $9.075 -2.42% 24
13/26/13 $9.300 +6.90% 24

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Evofem Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. EVFM.D Stock